Level	Gene	Alterations	Cancer Types	Drugs (for therapeutic implications only)
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Imatinib
1	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Ponatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Asciminib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Bosutinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Dasatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Imatinib
1	ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	Nilotinib
1	ABL1	T315I	B-Lymphoblastic Leukemia/Lymphoma	Ponatinib
1	ABL1	T315I	Chronic Myelogenous Leukemia	Asciminib
1	ABL1	T315I	Chronic Myelogenous Leukemia	Ponatinib
1	ALK	Fusions	Anaplastic Large-Cell Lymphoma ALK Positive	Crizotinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Alectinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Brigatinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Ceritinib
1	ALK	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	ALK	Oncogenic Mutations	Non-Small Cell Lung Cancer	Lorlatinib
1	ATM	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BARD1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BRAF	V600	Erdheim-Chester Disease	Vemurafenib
1	BRAF	V600	Melanoma	Vemurafenib + Atezolizumab + Cobimetinib
1	BRAF	V600E	Anaplastic Thyroid Cancer	Dabrafenib + Trametinib
1	BRAF	V600E	Colorectal Cancer	Encorafenib + Cetuximab
1	BRAF	V600E	Melanoma	Dabrafenib
1	BRAF	V600E	Melanoma	Vemurafenib
1	BRAF	V600E	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib
1	BRAF	V600E, V600K	Melanoma	Dabrafenib + Trametinib
1	BRAF	V600E, V600K	Melanoma	Encorafenib + Binimetinib
1	BRAF	V600E, V600K	Melanoma	Trametinib
1	BRAF	V600E, V600K	Melanoma	Vemurafenib + Cobimetinib
1	BRCA1	Oncogenic Mutations	Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma	Niraparib
1	BRCA1	Oncogenic Mutations	Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma	Olaparib, Olaparib + Bevacizumab
1	BRCA1	Oncogenic Mutations	Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma	Rucaparib
1	BRCA1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BRCA1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Rucaparib
1	BRCA2	Oncogenic Mutations	Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma	Niraparib
1	BRCA2	Oncogenic Mutations	Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma	Olaparib, Olaparib + Bevacizumab
1	BRCA2	Oncogenic Mutations	Ovary/Fallopian Tube, Ovarian Cancer, Peritoneal Serous Carcinoma	Rucaparib
1	BRCA2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	BRCA2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Rucaparib
1	BRIP1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CDK12	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CHEK1	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	CHEK2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Dacomitinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Erlotinib, Erlotinib + Ramucirumab
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Gefitinib
1	EGFR	Exon 19 in-frame deletions, L858R	Non-Small Cell Lung Cancer	Osimertinib
1	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Amivantamab
1	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Mobocertinib
1	EGFR	G719	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	L861Q	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	S768I	Non-Small Cell Lung Cancer	Afatinib
1	EGFR	T790M	Non-Small Cell Lung Cancer	Osimertinib
1	ERBB2	Amplification	Breast Cancer	Ado-Trastuzumab Emtansine
1	ERBB2	Amplification	Breast Cancer	Lapatinib + Capecitabine, Lapatinib + Letrozole
1	ERBB2	Amplification	Breast Cancer	Margetuximab + Chemotherapy
1	ERBB2	Amplification	Breast Cancer	Neratinib, Neratinib + Capecitabine
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Pertuzumab + Chemotherapy
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Tucatinib + Capecitabine
1	ERBB2	Amplification	Breast Cancer	Trastuzumab Deruxtecan
1	ERBB2	Amplification	Breast Cancer	Trastuzumab, Trastuzumab + Chemotherapy
1	ERBB2	Amplification	Esophagogastric Cancer	Pembrolizumab + Trastuzumab + Chemotherapy
1	ERBB2	Amplification	Esophagogastric Cancer	Trastuzumab + Chemotherapy
1	ERBB2	Amplification	Esophagogastric Cancer	Trastuzumab Deruxtecan
1	EZH2	A682G, A692V, Y646C, Y646F, Y646H, Y646N, Y646S	Follicular Lymphoma	Tazemetostat
1	FANCL	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	FGFR2	Fusions	Bladder Cancer	Erdafitinib
1	FGFR2	Fusions	Cholangiocarcinoma	Infigratinib
1	FGFR2	Fusions	Cholangiocarcinoma	Pemigatinib
1	FGFR3	Fusions	Bladder Cancer	Erdafitinib
1	FGFR3	G370C, R248C, S249C, Y373C	Bladder Cancer	Erdafitinib
1	FLT3	D835, I836, Internal tandem duplication	Acute Myeloid Leukemia	Gilteritinib
1	FLT3	D835, I836, Internal tandem duplication	Acute Myeloid Leukemia	Midostaurin + High Dose Chemotherapy
1	IDH1	R132	Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma	Ivosidenib
1	IDH1	R132C, R132G, R132H, R132L, R132S	Acute Myeloid Leukemia	Ivosidenib
1	IDH2	R140G, R140L, R140Q, R140W, R172G, R172K, R172M, R172S, R172W	Acute Myeloid Leukemia	Enasidenib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	A502_Y503dup, K509I, N505I, S476I, S501_A502dup	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 in-frame deletions, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, X550_splice, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 in-frame deletions, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, X550_splice, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 in-frame deletions, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, X550_splice, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	D572A, D572_P573dup, D579_H580insFNPTQLPYD, D579_H580insLPCD, D579del, E554_I571del, E554_K558del, E554_V559del, Exon 11 in-frame deletions, I563_L576del, K550_K558del, K550_V555delinsI, K550_W557del, K558N, K558_E562del, K558_V559del, K558_V560del, K558delinsNP, L576P, L576del, M552_K558del, M552_W557del, N564_Y578del, P551_E554del, P551_M552del, P551_V555del, P551_W557delinsL, P573Q, P573_D579del, P577_D579del, P577_R588dup, P577_W582delinsPYD, Q556_K558del, Q575_L576dup, Q575_P585dup, T574_R588delinsL, T574insTQLPYD, V555_L576del, V555_V559del, V559A, V559C, V559D, V559F, V559G, V559I, V559_G565del, V559_V560del, V559del, V560D, V560E, V560G, V560del, V569_L576del, W557C, W557G, W557R, W557_K558del, W557_V559delinsC, W557_V560del, X550_splice, Y553_K558del, Y553_Q556del, Y568_L576delinsVN, Y578C, Y578_D579dup, Y578_D579insEQQLPY	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	D816	Mastocytosis	Avapritinib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	K642E	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	T670I	Gastrointestinal Stromal Tumor	Sunitinib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Imatinib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Regorafenib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Ripretinib
1	KIT	V654A	Gastrointestinal Stromal Tumor	Sunitinib
1	KRAS	G12C	Non-Small Cell Lung Cancer	Sotorasib
1	KRAS	Wildtype	Colorectal Cancer	Cetuximab, Cetuximab + Chemotherapy
1	KRAS	Wildtype	Colorectal Cancer	Panitumumab, Panitumumab + Chemotherapy
1	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Capmatinib
1	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Tepotinib
1	NF1	Oncogenic Mutations	Neurofibroma	Selumetinib
1	NRAS	Wildtype	Colorectal Cancer	Panitumumab, Panitumumab + Chemotherapy
1	NTRK1	Fusions	All Solid Tumors	Entrectinib
1	NTRK1	Fusions	All Solid Tumors	Larotrectinib
1	NTRK2	Fusions	All Solid Tumors	Entrectinib
1	NTRK2	Fusions	All Solid Tumors	Larotrectinib
1	NTRK3	Fusions	All Solid Tumors	Entrectinib
1	NTRK3	Fusions	All Solid Tumors	Larotrectinib
1	Other Biomarkers	Microsatellite Instability-High	All Solid Tumors	Pembrolizumab
1	Other Biomarkers	Microsatellite Instability-High	Colorectal Cancer	Ipilimumab + Nivolumab
1	Other Biomarkers	Microsatellite Instability-High	Colorectal Cancer	Nivolumab
1	Other Biomarkers	Tumor Mutational Burden-High	All Solid Tumors	Pembrolizumab
1	PALB2	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	PDGFB	COL1A1-PDGFB Fusion	Dermatofibrosarcoma Protuberans	Imatinib
1	PDGFRA	Exon 18 in-frame deletions, Exon 18 in-frame insertions, Exon 18 missense mutations	Gastrointestinal Stromal Tumor	Avapritinib
1	PDGFRA	FIP1L1-PDGFRA Fusion	Chronic Eosinophilic Leukemia, NOS	Imatinib
1	PDGFRA	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib
1	PDGFRB	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib
1	PIK3CA	C420R, E542K, E545A, E545D, E545G, E545K, H1047L, H1047R, H1047Y, Q546E, Q546R	Breast Cancer	Alpelisib + Fulvestrant
1	RAD51B	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RAD51C	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RAD51D	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RAD54L	Oncogenic Mutations	Prostate Cancer, NOS, Prostate Cancer	Olaparib
1	RET	Fusions	Non-Small Cell Lung Cancer	Pralsetinib
1	RET	Fusions	Non-Small Cell Lung Cancer	Selpercatinib
1	RET	Fusions	Thyroid Cancer	Pralsetinib
1	RET	Fusions	Thyroid Cancer	Selpercatinib
1	RET	Oncogenic Mutations	Medullary Thyroid Cancer	Pralsetinib
1	RET	Oncogenic Mutations	Medullary Thyroid Cancer	Selpercatinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Crizotinib
1	ROS1	Fusions	Non-Small Cell Lung Cancer	Entrectinib
1	SMARCB1	Deletion	Epithelioid Sarcoma	Tazemetostat
1	TSC1	Oncogenic Mutations	Encapsulated Glioma	Everolimus
1	TSC2	Oncogenic Mutations	Encapsulated Glioma	Everolimus
2	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Bosutinib
2	ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib
2	ABL1	E255K, E255V, F317C, F317I, F317V, F359C, F359I, F359V, T315A, Y253H	B-Lymphoblastic Leukemia/Lymphoma	Bosutinib
2	ABL1	E255K, E255V, F317C, F317I, F317V, F359C, F359I, F359V, T315A, Y253H	Chronic Myelogenous Leukemia	Bosutinib
2	ABL1	E255K, E255V, F359C, F359I, F359V, Y253H	B-Lymphoblastic Leukemia/Lymphoma	Dasatinib
2	ABL1	E255K, E255V, F359C, F359I, F359V, Y253H	Chronic Myelogenous Leukemia	Dasatinib
2	ABL1	F317C, F317I, F317L, F317V, T315A, V299L	B-Lymphoblastic Leukemia/Lymphoma	Nilotinib
2	ABL1	F317C, F317I, F317L, F317V, T315A, V299L	Chronic Myelogenous Leukemia	Nilotinib
2	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Brigatinib
2	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Ceritinib
2	ALK	Fusions	Inflammatory Myofibroblastic Tumor	Crizotinib
2	ARAF	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	ARAF	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	ARAF	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	BRAF	Fusions	Pilocytic Astrocytoma	Selumetinib
2	BRAF	Oncogenic Mutations (excluding V600)	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	BRAF	Oncogenic Mutations (excluding V600)	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	BRAF	Oncogenic Mutations (excluding V600)	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	BRAF	V600	Langerhans Cell Histiocytosis	Vemurafenib, Dabrafenib
2	BRAF	V600 (excluding V600E and V600K)	Melanoma	Dabrafenib + Trametinib
2	BRAF	V600 (excluding V600E and V600K)	Melanoma	Encorafenib + Binimetinib
2	BRAF	V600 (excluding V600E and V600K)	Melanoma	Vemurafenib + Cobimetinib
2	BRAF	V600E	Colorectal Cancer	Encorafenib + Panitumumab
2	BRAF	V600E	Diffuse Glioma	Dabrafenib + Trametinib, Vemurafenib + Cobimetinib
2	BRAF	V600E	Encapsulated Glioma	Dabrafenib + Trametinib, Vemurafenib + Cobimetinib
2	BRAF	V600E	Ganglioglioma, Pleomorphic Xanthoastrocytoma, Pilocytic Astrocytoma	Dabrafenib + Trametinib, Vemurafenib + Cobimetinib
2	BRAF	V600E	Hairy Cell Leukemia	Vemurafenib
2	BRAF	V600E	Pilocytic Astrocytoma	Selumetinib
2	BRCA1	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Rucaparib
2	BRCA2	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Rucaparib
2	BRCA2	Oncogenic Mutations	Uterine Sarcoma	Olaparib, Rucaparib, Niraparib
2	EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	Erlotinib
2	ERBB2	Amplification	Colorectal Cancer	Lapatinib + Trastuzumab
2	ERBB2	Amplification	Colorectal Cancer	Trastuzumab + Pertuzumab
2	ERBB2	Amplification	Colorectal Cancer	Trastuzumab Deruxtecan
2	ERBB2	Amplification	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	Trastuzumab + Carboplatin-Taxol Regimen
2	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Ado-Trastuzumab Emtansine
2	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Trastuzumab Deruxtecan
2	EZH2	Oncogenic Mutations (excluding Y646S, Y646H, Y646C, Y646F, Y646N, A682G and A692V)	Follicular Lymphoma	Tazemetostat
2	FGFR1	Fusions	Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement	Pemigatinib
2	IDH1	Oncogenic Mutations	Chondrosarcoma	Ivosidenib
2	JAK2	Fusions	Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2	Ruxolitinib, Fedratinib
2	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Sorafenib
2	KIT	D579del, K642E, L576P, L576del, P577del, V559A, V560D, V560G, V560del, V654A, W557G, W557R, Y553_K558del	Melanoma	Imatinib
2	KRAS	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	KRAS	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	KRAS	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	MAP2K1	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	MAP2K1	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	MAP2K1	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	MAP2K2	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	MAP2K2	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	MAP2K2	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	MET	Amplification	Non-Small Cell Lung Cancer	Crizotinib
2	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations	Non-Small Cell Lung Cancer	Crizotinib
2	NRAS	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	NRAS	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	NRAS	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	PALB2	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Rucaparib
2	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Dasatinib
2	PDGFRA	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Imatinib
2	PDGFRA	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Regorafenib
2	PDGFRA	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Ripretinib
2	PDGFRA	Oncogenic Mutations	Gastrointestinal Stromal Tumor	Sunitinib
2	PIK3CA	Oncogenic Mutations (excluding C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R and H1047Y)	Breast Cancer	Alpelisib + Fulvestrant
2	RAF1	Oncogenic Mutations	Erdheim-Chester Disease	Cobimetinib, Trametinib
2	RAF1	Oncogenic Mutations	Langerhans Cell Histiocytosis	Cobimetinib, Trametinib
2	RAF1	Oncogenic Mutations	Rosai-Dorfman Disease	Cobimetinib, Trametinib
2	RET	Fusions	Non-Small Cell Lung Cancer	Cabozantinib
3	AKT1	E17K	Breast Cancer	AZD5363
3	AKT1	E17K	Ovarian Cancer, Endometrial Cancer	AZD5363
3	ARAF	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	ARAF	Oncogenic Mutations	Histiocytosis	Sorafenib
3	ARAF	Oncogenic Mutations	Non-Small Cell Lung Cancer	Sorafenib
3	BRAF	Fusions	Melanoma	Trametinib, Cobimetinib
3	BRAF	Fusions	Ovarian Cancer	Trametinib, Cobimetinib
3	BRAF	K601	Melanoma	Trametinib
3	BRAF	L597	Melanoma	Trametinib
3	BRAF	Oncogenic Mutations (excluding V600)	Histiocytosis	Cobimetinib, Trametinib
3	BRAF	V600	Histiocytosis	Vemurafenib, Dabrafenib
3	BRAF	V600E	Biliary Tract Cancer, NOS	Dabrafenib + Trametinib
3	BRCA1	Oncogenic Mutations	Breast Cancer	Olaparib
3	BRCA1	Oncogenic Mutations	Breast Cancer	Talazoparib
3	BRCA1	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Olaparib
3	BRCA2	Oncogenic Mutations	Breast Cancer	Olaparib
3	BRCA2	Oncogenic Mutations	Breast Cancer	Talazoparib
3	BRCA2	Oncogenic Mutations	Pancreatic Adenocarcinoma, Acinar Cell Carcinoma of the Pancreas	Olaparib
3	EGFR	E709_T710delinsD	Non-Small Cell Lung Cancer	Afatinib
3	EGFR	Exon 19 in-frame deletions, Exon 19 in-frame insertions, G719, L858R, L861Q, S768I	Non-Small Cell Lung Cancer	Patritumab Deruxtecan
3	EGFR	Exon 19 in-frame insertions	Non-Small Cell Lung Cancer	Erlotinib
3	EGFR	Exon 19 in-frame insertions	Non-Small Cell Lung Cancer	Gefitinib
3	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	CLN-081
3	EGFR	Exon 20 in-frame insertions	Non-Small Cell Lung Cancer	Poziotinib
3	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Afatinib
3	ERBB2	Oncogenic Mutations	Breast Cancer	Neratinib
3	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Neratinib
3	ERBB2	Oncogenic Mutations	Non-Small Cell Lung Cancer	Trastuzumab + Pertuzumab + Docetaxel
3	ERCC2	Oncogenic Mutations	Bladder Cancer	Cisplatin
3	ESR1	Oncogenic Mutations	Breast Cancer	AZD9496, Fulvestrant
3	FGFR1	Amplification	Lung Squamous Cell Carcinoma	Debio1347, Infigratinib, Erdafitinib
3	FGFR3	G380R, K650, S371C	Bladder Cancer	Erdafitinib
3	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Crenolanib
3	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Quizartinib
3	FLT3	Internal tandem duplication	Acute Myeloid Leukemia	Sorafenib
3	HRAS	Oncogenic Mutations	Bladder Urothelial Carcinoma	Tipifarnib
3	HRAS	Oncogenic Mutations	Head and Neck Squamous Cell Carcinoma	Tipifarnib
3	IDH1	R132	Glioma	Ivosidenib
3	JAK2	PCM1-JAK2 Fusion	Chronic Eosinophilic Leukemia, NOS	Ruxolitinib
3	KRAS	G12C	Colorectal Cancer	Adagrasib, Adagrasib + Cetuximab
3	KRAS	G12C	Hepatobiliary Cancer, Anal Cancer, Tubular Adenoma of the Colon, Gastrointestinal Neuroendocrine Tumor, Esophagogastric Cancer, Small Bowel Cancer	Adagrasib
3	KRAS	G12C	Non-Small Cell Lung Cancer	Adagrasib
3	KRAS	G12C	Pancreatic Adenocarcinoma	Adagrasib
3	KRAS	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	MAP2K1	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	MAP2K1	Oncogenic Mutations	Melanoma, Non-Small Cell Lung Cancer, Low-Grade Serous Ovarian Cancer	Trametinib, Cobimetinib
3	MAP2K2	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	MET	Y1003mut	Non-Small Cell Lung Cancer	Tepotinib, Capmatinib, Crizotinib
3	MTOR	E2014K, E2419K	Bladder Cancer	Everolimus
3	MTOR	L2209V, L2427Q	Renal Cell Carcinoma	Temsirolimus
3	MTOR	Q2223K	Renal Cell Carcinoma	Everolimus
3	NRAS	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	NRAS	Oncogenic Mutations	Melanoma	Binimetinib
3	NRAS	Oncogenic Mutations	Thyroid Cancer	Selumetinib + Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol
3	NRG1	Fusions	All Solid Tumors	Zenocutuzumab
3	PTCH1	Truncating Mutations	Medulloblastoma	Sonidegib, Vismodegib
3	RAF1	Oncogenic Mutations	Histiocytosis	Cobimetinib, Trametinib
3	RET	Fusions	Non-Small Cell Lung Cancer	Vandetanib
3	TSC2	Oncogenic Mutations	Perivascular Epithelioid Cell Tumor	ABI-009
4	ARID1A	Truncating Mutations	All Solid Tumors	PLX2853
4	ARID1A	Truncating Mutations	All Solid Tumors	Tazemetostat
4	BRAF	G464, G469A, G469R, G469V	All Solid Tumors	PLX8394
4	BRAF	K601	All Solid Tumors	PLX8394
4	BRAF	L597	All Solid Tumors	PLX8394
4	CDK12	Truncating Mutations	All Solid Tumors	Pembrolizumab, Nivolumab, Cemiplimab
4	CDK4	Amplification	Dedifferentiated Liposarcoma, Well-Differentiated Liposarcoma	Palbociclib, Abemaciclib
4	CDKN2A	Oncogenic Mutations	All Solid Tumors	Palbociclib, Ribociclib, Abemaciclib
4	EGFR	A289V, R108K, T263P	Glioma	Lapatinib
4	EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	Amplification	Glioma	Lapatinib
4	EGFR	D761Y	Non-Small Cell Lung Cancer	Osimertinib
4	EGFR	Exon 19 in-frame insertions	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Erlotinib
4	EGFR	Kinase Domain Duplication	Non-Small Cell Lung Cancer	Gefitinib
4	EGFR	L718V	Non-Small Cell Lung Cancer	Afatinib
4	EGFR	L747P	Non-Small Cell Lung Cancer	Afatinib
4	FGFR1	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FGFR2	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FGFR3	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FLI1	EWSR1-FLI1 Fusion	Ewing Sarcoma, Ewing Sarcoma of Soft Tissue	TK216
4	KDM6A	Oncogenic Mutations	Bladder Cancer	Tazemetostat
4	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Nilotinib
4	KIT	A829P, C809G, D816, D820, N822, Y823D	Gastrointestinal Stromal Tumor	Pazopanib
4	KRAS	Oncogenic Mutations	All Solid Tumors	Trametinib, Cobimetinib, Binimetinib
4	MDM2	Amplification	Dedifferentiated Liposarcoma, Well-Differentiated Liposarcoma	Milademetan
4	MET	Fusions	All Solid Tumors	Crizotinib
4	MTOR	Oncogenic Mutations	All Solid Tumors	Everolimus, Temsirolimus
4	NF1	Oncogenic Mutations	All Solid Tumors	Trametinib, Cobimetinib
4	NRAS	Oncogenic Mutations	Melanoma	Binimetinib + Ribociclib
4	PTEN	Oncogenic Mutations	All Solid Tumors	GSK2636771, AZD8186
4	SF3B1	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	SF3B1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	SF3B1	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	SMARCB1	Oncogenic Mutations	All Liquid Tumors	Tazemetostat
4	SRSF2	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	SRSF2	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	SRSF2	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	STK11	Oncogenic Mutations	Non-Small Cell Lung Cancer	Bemcentinib + Pembrolizumab
4	U2AF1	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	U2AF1	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	U2AF1	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800
4	ZRSR2	Oncogenic Mutations	Acute Myeloid Leukemia	H3B-8800
4	ZRSR2	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	H3B-8800
4	ZRSR2	Oncogenic Mutations	Myelodysplastic Syndromes	H3B-8800